January 8, 2025 01:14 PM EST

Astellas stops developing autologous cell therapy using tech from Xyphos buyout

Kyle LaHucik

Senior Reporter

Astellas has ended work on a cell therapy that it was exploring for CD20-positive B cell lymphomas, the Japan-based pharma confirmed to Endpoints News …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Astellas stops developing autologous cell therapy using tech from Xyphos buyout

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Exclusive: First-of-its-kind infant DNA edit leads to apparent cure in disease that set back field 25 years ago

Updated: Galapagos to split into two companies, slash headcount as it eyes turnaround

MaaT Pharma touts ‘unprecedented’ Phase 3 efficacy of graft-versus-host disease treatment

Gene editing startup Scribe Therapeutics lets go of staff as it preps for the clinic

FDA offers suite of new guidance on AI, accelerated approvals, clinical trials and more

Vir’s early T cell engager data offer first look at cancer pivot, stock jumps

Astel­las stops de­vel­op­ing au­tol­o­gous cell ther­a­py us­ing tech from Xyphos buy­out

Senior Reporter

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Astellas stops developing autologous cell therapy using tech from Xyphos buyout